Revvity (RVTY) Stock Overview
Provides health sciences solutions, technologies, and services. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RVTY Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Revvity, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$96.03 |
| 52 Week High | US$120.39 |
| 52 Week Low | US$81.36 |
| Beta | 1.09 |
| 1 Month Change | -14.64% |
| 3 Month Change | 3.19% |
| 1 Year Change | -14.46% |
| 3 Year Change | -28.04% |
| 5 Year Change | -25.97% |
| Change since IPO | 2,799.02% |
Recent News & Updates
Recent updates
Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?
Dec 18
Revvity: Software Momentum And Screening Offset China Weakness
Oct 27Revvity's (NYSE:RVTY) Performance Is Even Better Than Its Earnings Suggest
Aug 14Investors Interested In Revvity, Inc.'s (NYSE:RVTY) Earnings
Jul 22Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101?
Jul 04Calculating The Fair Value Of Revvity, Inc. (NYSE:RVTY)
Apr 25Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price
Apr 07Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?
Mar 20Revvity: Acquisitions In High-Growth Sectors, Excellent Debt Levels Create Notable Growth Potential
Feb 24Safe Biopharma: Revvity's Recurring Revenues And Diagnostics
Dec 16
Share Repurchases And AI Integration Propel Earnings And Revolutionize Diagnostics Growth
Aggressive share repurchase and implementation of AI-driven technologies could enhance shareholder value and operational efficiencies, leading to potential revenue growth.Shareholder Returns
| RVTY | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -6.6% | -6.9% | -1.3% |
| 1Y | -14.5% | -5.7% | 10.9% |
Return vs Industry: RVTY underperformed the US Life Sciences industry which returned -5.7% over the past year.
Return vs Market: RVTY underperformed the US Market which returned 10.9% over the past year.
Price Volatility
| RVTY volatility | |
|---|---|
| RVTY Average Weekly Movement | 5.5% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RVTY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RVTY's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1937 | 11,000 | Prahlad Singh | www.revvity.com |
Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
Revvity, Inc. Fundamentals Summary
| RVTY fundamental statistics | |
|---|---|
| Market cap | US$10.89b |
| Earnings (TTM) | US$239.88m |
| Revenue (TTM) | US$2.86b |
Is RVTY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVTY income statement (TTM) | |
|---|---|
| Revenue | US$2.86b |
| Cost of Revenue | US$1.29b |
| Gross Profit | US$1.56b |
| Other Expenses | US$1.32b |
| Earnings | US$239.88m |
Last Reported Earnings
Dec 28, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 54.77% |
| Net Profit Margin | 8.40% |
| Debt/Equity Ratio | 44.4% |
How did RVTY perform over the long term?
See historical performance and comparisonDividends
Does RVTY pay a reliable dividends?
See RVTY dividend history and benchmarks| Revvity dividend dates | |
|---|---|
| Ex Dividend Date | Apr 17 2026 |
| Dividend Pay Date | May 08 2026 |
| Days until Ex dividend | 59 days |
| Days until Dividend pay date | 80 days |
Does RVTY pay a reliable dividends?
See RVTY dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/16 20:48 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/12/28 |
| Annual Earnings | 2025/12/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revvity, Inc. is covered by 35 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |